Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Metastatic Colorectal Cancer

Phase 2

Recruiting

• Conditions: Metastatic Rectum Cancer; Metastatic Colon Cancer
• Interventions: Drug: Topical Tretinoin; Other: Placebo

• Registration Number: NCT06358677
• Lead Sponsor: University of Utah

Brief Summary

The goal of this clinical trial is to learn if using topical tretinoin will help patients with colorectal cancer who are experiencing an acneiform rash as a side effect of their treatment.

Researchers will compare the use of tretinoin on one side of the face to the use of a placebo on the other side of the face to see if there is an impact.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-04-04
• Study First Submitted QC: 2024-04-04
• Study First Posted: 2024-04-10
• Status Verified: 2024-06
• Study Start: 2024-06-21
• Last Update Submitted: 2024-06-21
• Last Update Posted: 2024-06-25
• Primary Completion: 2027-07
• Study Completion: 2029-07

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

• Participant aged ≥ 18 years

• Histologically confirmed colorectal cancer.

• Radiologically confirmed metastatic disease.

• Eligible for and willing to receive treatment with panitumumab or cetuximab as standard-of-care.

• ECOG Performance Status ≤ 2.

• Adequate organ function as defined as:

  --Hepatic:

  • Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN)
  • AST(SGOT)/ALT(SGPT) ≤ 3 × institutional ULN ----Participants with liver metastases will be allowed to enroll with AST and ALT levels ≤ 5 x ULN.

• Negative pregnancy test for participants who have not undergone surgical sterilization or shown evidence of post-menopausal status. The following age-specific requirements apply:

  --< 50 years of age:

  • Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and

  • Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution; or

  • Underwent surgical sterilization (bilateral oophorectomy or hysterectomy).

    --≥ 50 years of age:

  • Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or

  • Had radiation-induced menopause with last menses >1 year ago; or

  • Had chemotherapy-induced menopause with last menses >1 year ago; or

  • Underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).

• Participants of childbearing potential and participants with a sexual partner of childbearing potential must agree to use a highly effective method of contraception as described in Section 5.4.2.

• Must have recovered from adverse effects of any prior oncologic treatment (e.g. prior surgery, radiotherapy, or other antineoplastic therapy). CTCAE adverse events less than or equal to grade 1 are acceptable. CTCAE adverse events grade 2 or greater may be acceptable as determined by an investigator with appropriate documentation.

• Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.

Exclusion Criteria

• Prior treatment with an anti-EGFR agent.

• Pre-existing facial rash with an IGA score of >2 or that per the treating investigator would preclude the ability to assess response to topical tretinoin.

• The diagnosis of another malignancy within ≤ 2 years before study enrollment, except for those considered to be adequately treated with no evidence of disease or symptoms and/or will not require therapy during the study duration (i.e., basal cell or squamous cell skin cancer, carcinoma in situ of the breast, bladder or of the cervix, or low-grade prostate cancer with Gleason Score ≤ 6).

• Any other condition that would, in the Investigator's judgment, contraindicate the participant's participation in the clinical study due to safety concerns or compliance with clinical study procedures.

• Systemic active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination, radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), or hepatitis C.

  --Note: Participants with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Participants positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.

• Medical, psychiatric, cognitive, or other conditions that may compromise the participant's ability to understand the participant information, give informed consent, comply with the study protocol or complete the study.

• Known prior severe hypersensitivity to investigational product or any component in its formulations (CTCAE v5.0 Grade ≥ 3).

• Participants taking prohibited medications as described in Section 6.8.2. A washout period of prohibited medications for a period of at least five half-lives or as clinically indicated should occur before the start of treatment.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Tretinoin half of face (left) and Placebo/Moisturizer other half of the face (right)	Topical Tretinoin	Randomized, double-blind, split-face. Randomization will determine which side of the face Tretinoin will be applied to (left or right). The other side of the face (left or right) will have placebo applied. All participants will receive both treatment and placebo.
Tretinoin half of face (right) and Placebo/Moisturizer other half of the face (left)	Placebo	Randomized, double-blind, split-face. Randomization will determine which side of the face Tretinoin will be applied to (left or right). The other side of the face (left or right) will have placebo applied. All participants will receive both treatment and placebo.

Primary Outcome Measures

Name	Time	Method
The maximum difference in modified Investigators Global Assessment (IGA) score between the treated and untreated sides of the face at any assessment.	6 weeks	Effect of topical tretinoin on anti-EGFR induced acneiform rash. Rash will be scored from 0-4 with 0 being clear skin and 4 being a severe rash.

Secondary Outcome Measures

Name	Time	Method
Frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type, severity (as defined by the NIH CTCAE version 5.0 and the modified IGA), seriousness, duration, and relationship to study treatment.	6 weeks	Proportion of acneiform rash per CTCAE v5.0

Trial Locations

Locations (1)

Huntsman Cancer Institute at University of Utah; 🇺🇸 Salt Lake City, Utah, United States